Townsquare Capital LLC Has $4.45 Million Stock Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Townsquare Capital LLC increased its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 38.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 47,953 shares of the medical instruments supplier’s stock after buying an additional 13,210 shares during the quarter. Townsquare Capital LLC’s holdings in LeMaitre Vascular were worth $4,454,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in LMAT. NBC Securities Inc. grew its stake in LeMaitre Vascular by 73.2% in the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 183 shares during the period. GAMMA Investing LLC lifted its holdings in shares of LeMaitre Vascular by 57.0% during the 2nd quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock valued at $45,000 after purchasing an additional 199 shares in the last quarter. USA Financial Formulas acquired a new position in shares of LeMaitre Vascular in the 3rd quarter valued at approximately $60,000. West Oak Capital LLC acquired a new position in shares of LeMaitre Vascular in the 2nd quarter valued at approximately $58,000. Finally, nVerses Capital LLC increased its stake in LeMaitre Vascular by 33.3% during the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock worth $66,000 after purchasing an additional 200 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the transaction, the director now directly owns 2,278 shares of the company’s stock, valued at $231,148.66. This represents a 62.21 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 10.79% of the company’s stock.

LeMaitre Vascular Trading Up 0.4 %

NASDAQ:LMAT opened at $105.80 on Friday. The stock has a market capitalization of $2.38 billion, a PE ratio of 57.81, a P/E/G ratio of 2.62 and a beta of 0.89. LeMaitre Vascular, Inc. has a 1-year low of $51.70 and a 1-year high of $109.58. The firm has a fifty day simple moving average of $95.18 and a 200 day simple moving average of $87.68.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. The business had revenue of $54.82 million during the quarter, compared to analysts’ expectations of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. LeMaitre Vascular’s quarterly revenue was up 15.6% on a year-over-year basis. During the same quarter last year, the company posted $0.33 earnings per share. On average, equities analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st will be issued a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.60%. The ex-dividend date is Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio is 34.97%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on LMAT. Cantor Fitzgerald initiated coverage on shares of LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target on the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. JMP Securities increased their target price on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 20th. StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Finally, Barrington Research increased their price objective on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, LeMaitre Vascular presently has a consensus rating of “Moderate Buy” and an average target price of $94.57.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.